GPT and metabolic dysfunction-associated steatotic liver disease: Indeed, pemafibrate induced a significant reduction in alanine aminotransferase (ALT) and γ-glutamyl transpeptidase (γ-GTP) levels in NAFLD patients (11, 14–21).